Cingulate Inc. (CING) Research

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Market snapshot

Symbol
CING
Price
$4.99
Day change
-2.54%
Market cap
$28.0M
P/E ratio
-0.98x
52-week range
3.16-11.89
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$10.00

Recent news

  • US FDA declines to approve Cingulate's ADHD drug

    Cingulate ​said on ‌Tuesday that ​the ​U.S. Food ⁠and ​Drug Administration ​declined to approve ​its ​drug to ‌treat ⁠attention deficit hyperactivity ​disorder.

Peer companies

  • Allarity Therapeutics, Inc. (ALLR)
  • BriaCell Therapeutics Corp. (BCTX)
  • CASI Pharmaceuticals, Inc. (CASI)
  • Clearside Biomedical, Inc. (CLSD)
  • Entero Therapeutics, Inc. (ENTO)
  • Kairos Pharma, Ltd. (KAPA)
  • Lexaria Bioscience Corp. (LEXX)
  • Lixte Biotechnology Holdings, Inc. (LIXT)

Recent insider activity

  • Hargroves Thomas Jeffrey — P-Purchase (97276 shares) on 2026-02-13
  • Hargroves Thomas Jeffrey — P-Purchase (77821 shares) on 2026-02-13
  • Hargroves Thomas Jeffrey — A-Award (15000 shares) on 2026-03-09
  • Hargroves Thomas Jeffrey — trade (0 shares) on 2026-02-13
  • Hargroves Thomas Jeffrey — trade (35 shares) on 2021-12-10

Open Cingulate Inc. (CING) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.